Fw: CROI: Modified Microbicide Gel for Rectal Use Reported Safe in Study

[Guest guest]

From: AIDSmeds <news@...>Date: Wed, 7 Mar 2012 08:27:54 -0500<nelsonvergel@...>Subject: CROI: Modified Microbicide Gel for Rectal Use Reported Safe in Study Conference Coverage19th Conference on Retroviruses andOpportunistic InfectionsAIDSmeds is in Seattlethis week covering one of the most important annual HIV/AIDSresearch meetings: The 19th Conference on Retroviruses andOpportunistic Infections (CROI 2011). We are adding newarticles to our CROI2011 conference page at a steady clip—keepchecking in over the next few weeks as our coveragecontinues.CROI 2012 NewsMarch 6, 2012ModifiedTenofovir Gel for Rectal Use Safe and Acceptable in Phase IStudy A modified version of the Viread (tenofovir)microbicide for rectal use has been found to be safe byresearchers and acceptable by study volunteers who used thegel for seven days, according to new data from theMicrobicide Trials Network (MTN) reported Tuesday, May 6, atthe 19th Conference on Retroviruses and OpportunisticInfections (CROI) in Seattle. PartnersPrEP: Up to 90% Fewer Infections in Mixed-Status HeteroCouples Viread (tenofovir) and Truvada (tenofovirplus emtricitabine), when either was used as dailypre-exposure prophylaxis (PrEP), reduced the risk ofcontracting HIV by more than two thirds among mixed-statusheterosexual couples—and up to 90 percent among thosewith laboratory evidence of having actually taken theirallotted preventive treatment—according to new resultsfrom the Partners PrEP study reported on Tuesday, March 6,at the 19th Conference on Retroviruses and OpportunisticInfections (CROI) in Seattle. Incivek,Victrelis Studies Hint at Superior Cure Rates in HIV/HCVCoinfection Adding a protease inhibitor to pegylatedinterferon and ribavirin as part of hepatitis C virus (HCV)treatment resulted in higher sustained virologic responserates 12 weeks after finishing the regimen, pointing tosignificantly higher cure rates compared with thosereceiving pegylated interferon and ribavirin alone,according to results from two Phase II studies presentedTuesday, March 6, at the 19th Conference on Retroviruses andOpportunistic Infections in Seattle. More Treatment NewsMarch 6, 2012NewIAPAC Recommendations on Getting and Keeping People in Carefor HIV Addressing a key issue in the HIV/AIDSepidemic, the International Association of Physicians inAIDS Care (IAPAC) has released " Guidelines forImproving Entry Into and Retention in Care andAntiretroviral Adherence for Persons With HIV:Evidence-Based Recommendations. " MoreThan Half of People With HIV in U.S. Have Long Gaps inCare A first-ever comprehensive estimate of U.S.HIV care retention reveals that more than half ofHIV-positive patients had gaps in treatment ranging fromseven months to a year or more, according a new studypublished in the journal AIDS and reported in a Universityof Pennsylvania statement. March 5, 2012BritishHIV Groups Say PrEP Should Not Be Offered Yet The British HIV Association (BHIVA) and theBritish Association for Sexual Health and HIV (BASHH) haveissued a statement saying that efficacy data on pre-exposureprophylaxis (PrEP) is not compelling enough for PrEP to beoffered to patients on demand, aidsmap reports. EarlyAccess Program for Integrase Inhibitor DolutegravirLaunched ViiV Healthcare and Shionogi have launchedan expanded access program (EAP) for its integrase inhibitordolutegravir (S/GSK134957), according to details nowavailable on ViiV’s website. March 1, 2012Cholesterol-ReducingStatins, Other Meds to Be Avoided With Hep C ProteaseInhibitors Health care providers are being reminded notto prescribe certain cholesterol-reducingmedications—notably members of the“statin” drug class—for people living withhepatitis C virus (HCV) using either Incivek (telaprevir) orVictrelis (boceprevir), according to a recent U.S. Food andDrug Administration (FDA) letter. February 28, 2012U.K.Guidelines Expand 'Preferred' Treatment Options, EmphasizeTreatment as Prevention Treatment guidelines in the United Kingdomcontinue to recommend that people living with HIV startantiretroviral (ARV) therapy when the CD4 cell count fallsto 350 or below, though the preliminary version releasedFebruary 4 and reviewed by aidsmap also recommends thathealth care providers discuss the evidence that treatmentreduces the risk of HIV transmission at any CD4 level. ColonialismSparked the HIV/AIDS Pandemic A new book implicates colonial practices inthe early spread of HIV and argues that HIV would never havebecome a global pandemic without the mobility, urbanization,medical campaigns and prostitution introduced to centralAfrica by Europeans, The Washington Post reports.BritainProposes Free HIV Treatment for Non-citizens The British government is considering aproposal to lift the National Health Service (NHS) ban onproviding free HIV treatment to those living in the countrywithout British citizenship, The Telegraph reports. At your request,you are subscribed asnelsonvergel@... to the followingnewsletter(s): AIDSmeds NewsletterPlease remember to add news@... toyour e-mail address book, so that these updates aren'tblocked as spam.To change your subscription information and preferences,please visit lists.smartandstrong.com/?p=preferencesTo stop receiving this newsletter, please visit lists.smartandstrong.com/?p=unsubscribeClick thislink to forward this message to a friend. Did you receive this e-mail from a friend? Please visit lists.smartandstrong.com/?p=subscribe&id=9to signup for your own copy.Copyright 2012 Smart + Strong, 462 Seventh Avenue, 19thFloor, New York, NY 10018. All rights reserved. Terms OfUse and YourPrivacy.powered by phplist v2.10.17, © phpList ltd